8-K: BriaCell Consolidates Shares to Maintain Nasdaq Listing

BriaCell Therapeutics Corp. announced a 1-for-10 reverse stock split to ensure continued compliance with Nasdaq Capital Market listing requirements.

Summary

• BriaCell Therapeutics Corp. implemented a consolidation of its issued and outstanding common shares.
• The consolidation ratio is one (1) post-Consolidation Common Share for every ten (10) pre-Consolidation Common Shares.
• The primary objective of the consolidation is to ensure the company continues to comply with the listing requirements of The Nasdaq Capital Market.
• The consolidation became effective under the corporate law of British Columbia, Canada, on August 25, 2025.
• Post-Consolidation Common Shares commenced trading on the Toronto Stock Exchange (TSX) and The Nasdaq Capital Market at market open on August 25, 2025.
• A new CUSIP number, 107930307, has been assigned to the post-Consolidation Common Shares.
• Fractional Common Shares less than 0.5 will be cancelled, while those 0.5 or greater will be rounded up to one whole Common Share at the participant level.
• The exercise or conversion price and/or the number of Common Shares issuable under any outstanding convertible securities will be proportionately adjusted.
• The post-Consolidation Common Shares will continue to trade on the TSX under the symbol BCT and on the Nasdaq under the symbol BCTX.

Sentiment

Score: 3

Explanation: While the action prevents delisting, the necessity of a reverse stock split typically reflects poor stock performance and can be viewed negatively by the market, indicating underlying challenges rather than positive operational developments.

Positives

• The company took proactive action to maintain its listing on The Nasdaq Capital Market, preventing potential delisting.

Negatives

• A reverse stock split often indicates a low share price, which can be perceived negatively by investors and may reflect underlying challenges.
• Shareholders holding fractional shares less than 0.5 of a Common Share will have them cancelled, potentially resulting in a small loss.

Risks

• Risk of non-compliance with Nasdaq listing requirements if the consolidation had not been implemented.
• General risks and uncertainties associated with forward-looking statements, as detailed in the company's most recent Management's Discussion and Analysis, Annual Information Form, and other filings with Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission.

Future Outlook

The company anticipates that upon completion of the Consolidation, the post-Consolidation Common Shares will continue to trade on the TSX under the symbol BCT and on the Nasdaq under the symbol BCTX.

Management Comments

• The Company's board of directors has approved the consolidation of the Company's issued and outstanding common shares on the basis of one (1) post-Consolidation Common Share for every ten (10) pre-Consolidation Common Shares.
• The Consolidation is being implemented to ensure that the Company continues to comply with the listing requirements of The Nasdaq Capital Market (the Nasdaq).

Industry Context

Reverse stock splits are a common strategy employed by companies, particularly in the biotechnology sector, to meet minimum bid price requirements of major stock exchanges like Nasdaq. This action aims to prevent delisting, which can severely impact a company's ability to raise capital and its public visibility. While necessary for compliance, it often signals underlying challenges with stock performance.

Corporate Governance

Stakeholder Impact

• Shareholders will hold fewer shares, but each share will have a proportionately higher value. Fractional shares may be cancelled or rounded up.
• Investors may view the reverse stock split as a necessary step to maintain listing, but also as an indicator of past stock underperformance.

Next Steps

• Shareholders of record as of the Effective Date will receive a letter of transmittal from Computershare Investor Services Inc. providing instructions for the exchange of their Common Shares.
• Beneficial holders who hold their Common Shares through intermediaries should contact their intermediaries with respect to the Consolidation.

Key Dates

Recommendation

The reverse stock split is a defensive measure to maintain Nasdaq listing, preventing a more severe negative event (delisting). While it addresses a compliance issue, it does not fundamentally alter the company's operational or financial performance. Investors should hold to observe the company's progress in its clinical-stage biotechnology development, as the core value driver remains its immunotherapy pipeline. The action itself is not a catalyst for significant upside but mitigates a downside risk.

Keywords

BriaCell Therapeutics, BCTX, BCT, Nasdaq, TSX, Share Consolidation, Reverse Stock Split, Listing Compliance, Biotechnology, Immunotherapies, Cancer Care